No Data
No Data
Sellas Life Sciences' Potential Leukemia Treatment Receives Second Rare Pediatric Disease Designation
Sellas Life Sciences Group (SLS) said Tuesday that the US Food and Drug Administration granted a rare pediatric disease designation to the company's SLS009 for the treatment of acute myeloid
Express News | SELLAS Life Sciences Group Shares Are Trading Higher After the Company Announced the FDA Granted Rare Pediatric Disease Designation to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
Express News | Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Sls009 for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS' SLS009 Granted Orphan Drug Designation by EMA for Acute Myeloid Leukemia Treatment
Express News | SELLAS Life Sciences Granted Orphan Drug Designation By European Commission For SLS009, A Novel CDK9 Inhibitor For Treating Acute Myeloid Leukemia
Express News | Sellas Life Sciences Group Inc: On Track to Share Further Data Around Sls009 in Q3 of This Year
No Data